nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—NT5E—Pyrimidine catabolism—NT5C3A—bone cancer	0.115	0.219	CbGpPWpGaD
Pentoxifylline—NT5E—Pyrimidine metabolism—NT5C3A—bone cancer	0.0661	0.126	CbGpPWpGaD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.0512	0.0975	CbGpPWpGaD
Pentoxifylline—NT5E—periosteum—bone cancer	0.0419	0.357	CbGeAlD
Pentoxifylline—NT5E—cartilage tissue—bone cancer	0.0294	0.25	CbGeAlD
Pentoxifylline—ADORA2A—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.0289	0.055	CbGpPWpGaD
Pentoxifylline—NT5E—Nucleotide metabolism—NT5C3A—bone cancer	0.0258	0.049	CbGpPWpGaD
Pentoxifylline—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.0153	0.0291	CbGpPWpGaD
Pentoxifylline—NT5E—Differentiation Pathway—IL3—bone cancer	0.0131	0.0249	CbGpPWpGaD
Pentoxifylline—NT5E—Differentiation Pathway—KIT—bone cancer	0.00763	0.0145	CbGpPWpGaD
Pentoxifylline—NT5E—connective tissue—bone cancer	0.00731	0.0622	CbGeAlD
Pentoxifylline—ADORA1—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00583	0.0111	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00562	0.0107	CbGpPWpGaD
Pentoxifylline—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00503	0.00956	CbGpPWpGaD
Pentoxifylline—NT5E—tendon—bone cancer	0.00503	0.0427	CbGeAlD
Pentoxifylline—NT5E—bone marrow—bone cancer	0.00487	0.0414	CbGeAlD
Pentoxifylline—NT5E—spinal cord—bone cancer	0.00485	0.0412	CbGeAlD
Pentoxifylline—PDE5A—connective tissue—bone cancer	0.00475	0.0403	CbGeAlD
Pentoxifylline—ADORA2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.0045	0.00855	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCRs, Other—GRM1—bone cancer	0.00445	0.00847	CbGpPWpGaD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—RGS1—bone cancer	0.00429	0.00817	CbGpPWpGaD
Pentoxifylline—NT5E—HIF-1-alpha transcription factor network—JUN—bone cancer	0.00405	0.0077	CbGpPWpGaD
Pentoxifylline—PDE4A—G Protein Signaling Pathways—GNA11—bone cancer	0.0039	0.00742	CbGpPWpGaD
Pentoxifylline—PDE4B—G Protein Signaling Pathways—GNA11—bone cancer	0.00361	0.00686	CbGpPWpGaD
Pentoxifylline—ADORA2A—spinal cord—bone cancer	0.00345	0.0294	CbGeAlD
Pentoxifylline—PDE5A—tendon—bone cancer	0.00326	0.0277	CbGeAlD
Pentoxifylline—ADORA2A—GPCRs, Other—SMO—bone cancer	0.00314	0.00597	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—GRM4—bone cancer	0.00311	0.00592	CbGpPWpGaD
Pentoxifylline—ADORA1—G alpha (i) signalling events—RGS1—bone cancer	0.00311	0.00592	CbGpPWpGaD
Pentoxifylline—ADORA1—tendon—bone cancer	0.00309	0.0263	CbGeAlD
Pentoxifylline—ADORA1—spinal cord—bone cancer	0.00298	0.0254	CbGeAlD
Pentoxifylline—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.0029	0.00552	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—NDUFA12—bone cancer	0.00282	0.00537	CbGpPWpGaD
Pentoxifylline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00272	0.00517	CbGpPWpGaD
Pentoxifylline—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.00264	0.00502	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00253	0.00481	CbGpPWpGaD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—KIT—bone cancer	0.00247	0.00469	CbGpPWpGaD
Pentoxifylline—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.00243	0.00462	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—NT5C3A—bone cancer	0.00234	0.00445	CbGpPWpGaD
Pentoxifylline—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.00233	0.00444	CbGpPWpGaD
Pentoxifylline—PDE4B—tendon—bone cancer	0.00229	0.0194	CbGeAlD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—ATF1—bone cancer	0.00223	0.00424	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—GRM4—bone cancer	0.00222	0.00422	CbGpPWpGaD
Pentoxifylline—PDE4B—bone marrow—bone cancer	0.00222	0.0188	CbGeAlD
Pentoxifylline—PDE4B—spinal cord—bone cancer	0.00221	0.0188	CbGeAlD
Pentoxifylline—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.00216	0.00412	CbGpPWpGaD
Pentoxifylline—Cramps of lower extremities—Epirubicin—bone cancer	0.00212	0.00595	CcSEcCtD
Pentoxifylline—Eructation—Doxorubicin—bone cancer	0.0021	0.00588	CcSEcCtD
Pentoxifylline—Flushing—Cisplatin—bone cancer	0.00209	0.00587	CcSEcCtD
Pentoxifylline—Salivary hypersecretion—Doxorubicin—bone cancer	0.00207	0.00582	CcSEcCtD
Pentoxifylline—Influenza like illness—Doxorubicin—bone cancer	0.00207	0.00582	CcSEcCtD
Pentoxifylline—Immune system disorder—Cisplatin—bone cancer	0.00204	0.00572	CcSEcCtD
Pentoxifylline—Arrhythmia—Cisplatin—bone cancer	0.00202	0.00565	CcSEcCtD
Pentoxifylline—Aplastic anaemia—Doxorubicin—bone cancer	0.00201	0.00562	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—GNA11—bone cancer	0.00197	0.00375	CbGpPWpGaD
Pentoxifylline—Erythema—Cisplatin—bone cancer	0.00196	0.00551	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—EZH2—bone cancer	0.00196	0.00373	CbGpPWpGaD
Pentoxifylline—Cramps of lower extremities—Doxorubicin—bone cancer	0.00196	0.0055	CcSEcCtD
Pentoxifylline—Flatulence—Cisplatin—bone cancer	0.00194	0.00543	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR ligand binding—GRM1—bone cancer	0.00192	0.00366	CbGpPWpGaD
Pentoxifylline—Muscle spasms—Cisplatin—bone cancer	0.00189	0.0053	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—GRM4—bone cancer	0.00189	0.00359	CbGpPWpGaD
Pentoxifylline—Vascular purpura—Epirubicin—bone cancer	0.00187	0.00525	CcSEcCtD
Pentoxifylline—ADORA2B—C-MYB transcription factor network—PTGS2—bone cancer	0.00187	0.00356	CbGpPWpGaD
Pentoxifylline—Vision blurred—Cisplatin—bone cancer	0.00185	0.00519	CcSEcCtD
Pentoxifylline—Anaphylactoid reaction—Methotrexate—bone cancer	0.00185	0.00519	CcSEcCtD
Pentoxifylline—Tremor—Cisplatin—bone cancer	0.00184	0.00516	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Cisplatin—bone cancer	0.00182	0.00511	CcSEcCtD
Pentoxifylline—Anaemia—Cisplatin—bone cancer	0.00182	0.00509	CcSEcCtD
Pentoxifylline—PDE5A—Hemostasis—SPARC—bone cancer	0.00182	0.00345	CbGpPWpGaD
Pentoxifylline—Malaise—Cisplatin—bone cancer	0.00177	0.00497	CcSEcCtD
Pentoxifylline—Leukopenia—Cisplatin—bone cancer	0.00176	0.00493	CcSEcCtD
Pentoxifylline—Purpura—Epirubicin—bone cancer	0.00174	0.00488	CcSEcCtD
Pentoxifylline—Vascular purpura—Doxorubicin—bone cancer	0.00173	0.00486	CcSEcCtD
Pentoxifylline—Anaphylactoid reaction—Epirubicin—bone cancer	0.00173	0.00485	CcSEcCtD
Pentoxifylline—Convulsion—Cisplatin—bone cancer	0.0017	0.00477	CcSEcCtD
Pentoxifylline—Myalgia—Cisplatin—bone cancer	0.00167	0.00469	CcSEcCtD
Pentoxifylline—Anxiety—Cisplatin—bone cancer	0.00167	0.00468	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00166	0.00466	CcSEcCtD
Pentoxifylline—PDE5A—Hemostasis—GNA11—bone cancer	0.00166	0.00316	CbGpPWpGaD
Pentoxifylline—Discomfort—Cisplatin—bone cancer	0.00165	0.00464	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—GRM1—bone cancer	0.00163	0.00311	CbGpPWpGaD
Pentoxifylline—Purpura—Doxorubicin—bone cancer	0.00161	0.00451	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Cisplatin—bone cancer	0.0016	0.0045	CcSEcCtD
Pentoxifylline—Oedema—Cisplatin—bone cancer	0.0016	0.0045	CcSEcCtD
Pentoxifylline—Anaphylactoid reaction—Doxorubicin—bone cancer	0.0016	0.00449	CcSEcCtD
Pentoxifylline—Infection—Cisplatin—bone cancer	0.00159	0.00447	CcSEcCtD
Pentoxifylline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00159	0.00302	CbGpPWpGaD
Pentoxifylline—Thrombocytopenia—Cisplatin—bone cancer	0.00157	0.0044	CcSEcCtD
Pentoxifylline—Tachycardia—Cisplatin—bone cancer	0.00157	0.00439	CcSEcCtD
Pentoxifylline—Skin disorder—Cisplatin—bone cancer	0.00156	0.00437	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Cisplatin—bone cancer	0.00155	0.00435	CcSEcCtD
Pentoxifylline—Anorexia—Cisplatin—bone cancer	0.00153	0.00429	CcSEcCtD
Pentoxifylline—ADORA2A—Circadian rythm related genes—GNA11—bone cancer	0.00152	0.0029	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—EZH2—bone cancer	0.00152	0.00288	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—IL3—bone cancer	0.00151	0.00286	CbGpPWpGaD
Pentoxifylline—Hypotension—Cisplatin—bone cancer	0.0015	0.0042	CcSEcCtD
Pentoxifylline—Abdominal discomfort—Methotrexate—bone cancer	0.00148	0.00416	CcSEcCtD
Pentoxifylline—Pancytopenia—Methotrexate—bone cancer	0.00147	0.00412	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00146	0.0041	CcSEcCtD
Pentoxifylline—Abdominal distension—Epirubicin—bone cancer	0.00146	0.00409	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—GRM4—bone cancer	0.00146	0.00277	CbGpPWpGaD
Pentoxifylline—Dyspnoea—Cisplatin—bone cancer	0.00143	0.00401	CcSEcCtD
Pentoxifylline—Angina pectoris—Epirubicin—bone cancer	0.00141	0.00396	CcSEcCtD
Pentoxifylline—Decreased appetite—Cisplatin—bone cancer	0.00139	0.00391	CcSEcCtD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	0.00139	0.00264	CbGpPWpGaD
Pentoxifylline—Drowsiness—Methotrexate—bone cancer	0.00138	0.00387	CcSEcCtD
Pentoxifylline—Infestation—Methotrexate—bone cancer	0.00138	0.00387	CcSEcCtD
Pentoxifylline—Infestation NOS—Methotrexate—bone cancer	0.00138	0.00387	CcSEcCtD
Pentoxifylline—Pancytopenia—Epirubicin—bone cancer	0.00138	0.00386	CcSEcCtD
Pentoxifylline—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00137	0.0026	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR ligand binding—SMO—bone cancer	0.00135	0.00258	CbGpPWpGaD
Pentoxifylline—Abdominal distension—Doxorubicin—bone cancer	0.00135	0.00378	CcSEcCtD
Pentoxifylline—Conjunctivitis—Methotrexate—bone cancer	0.00134	0.00376	CcSEcCtD
Pentoxifylline—Sweating—Methotrexate—bone cancer	0.00132	0.00371	CcSEcCtD
Pentoxifylline—Feeling abnormal—Cisplatin—bone cancer	0.00132	0.00371	CcSEcCtD
Pentoxifylline—Angina pectoris—Doxorubicin—bone cancer	0.00131	0.00366	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Methotrexate—bone cancer	0.0013	0.00366	CcSEcCtD
Pentoxifylline—Epistaxis—Methotrexate—bone cancer	0.0013	0.00365	CcSEcCtD
Pentoxifylline—Drowsiness—Epirubicin—bone cancer	0.00129	0.00362	CcSEcCtD
Pentoxifylline—Infestation—Epirubicin—bone cancer	0.00129	0.00362	CcSEcCtD
Pentoxifylline—Infestation NOS—Epirubicin—bone cancer	0.00129	0.00362	CcSEcCtD
Pentoxifylline—Pancytopenia—Doxorubicin—bone cancer	0.00127	0.00357	CcSEcCtD
Pentoxifylline—Body temperature increased—Cisplatin—bone cancer	0.00127	0.00356	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—GRM1—bone cancer	0.00126	0.0024	CbGpPWpGaD
Pentoxifylline—Jaundice—Epirubicin—bone cancer	0.00126	0.00353	CcSEcCtD
Pentoxifylline—Conjunctivitis—Epirubicin—bone cancer	0.00126	0.00352	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR downstream signaling—RGS1—bone cancer	0.00125	0.00238	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—GRM4—bone cancer	0.00125	0.00238	CbGpPWpGaD
Pentoxifylline—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.00125	0.00237	CbGpPWpGaD
Pentoxifylline—Haemoglobin—Methotrexate—bone cancer	0.00124	0.00349	CcSEcCtD
Pentoxifylline—Haemorrhage—Methotrexate—bone cancer	0.00124	0.00347	CcSEcCtD
Pentoxifylline—Hepatitis—Methotrexate—bone cancer	0.00124	0.00347	CcSEcCtD
Pentoxifylline—Sweating—Epirubicin—bone cancer	0.00124	0.00347	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Epirubicin—bone cancer	0.00122	0.00342	CcSEcCtD
Pentoxifylline—Epistaxis—Epirubicin—bone cancer	0.00122	0.00342	CcSEcCtD
Pentoxifylline—Infestation NOS—Doxorubicin—bone cancer	0.00119	0.00335	CcSEcCtD
Pentoxifylline—Infestation—Doxorubicin—bone cancer	0.00119	0.00335	CcSEcCtD
Pentoxifylline—Drowsiness—Doxorubicin—bone cancer	0.00119	0.00335	CcSEcCtD
Pentoxifylline—Hypersensitivity—Cisplatin—bone cancer	0.00118	0.00331	CcSEcCtD
Pentoxifylline—Haemoglobin—Epirubicin—bone cancer	0.00117	0.00327	CcSEcCtD
Pentoxifylline—Jaundice—Doxorubicin—bone cancer	0.00116	0.00327	CcSEcCtD
Pentoxifylline—Conjunctivitis—Doxorubicin—bone cancer	0.00116	0.00326	CcSEcCtD
Pentoxifylline—Haemorrhage—Epirubicin—bone cancer	0.00116	0.00325	CcSEcCtD
Pentoxifylline—Hepatitis—Epirubicin—bone cancer	0.00116	0.00325	CcSEcCtD
Pentoxifylline—ADORA1—GPCR ligand binding—SMO—bone cancer	0.00115	0.00219	CbGpPWpGaD
Pentoxifylline—Asthenia—Cisplatin—bone cancer	0.00115	0.00323	CcSEcCtD
Pentoxifylline—Sweating—Doxorubicin—bone cancer	0.00115	0.00321	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling by GPCR—RGS1—bone cancer	0.00114	0.00216	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—GRM4—bone cancer	0.00114	0.00216	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—RGS1—bone cancer	0.00114	0.00216	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—GRM4—bone cancer	0.00114	0.00216	CbGpPWpGaD
Pentoxifylline—Hepatobiliary disease—Doxorubicin—bone cancer	0.00113	0.00317	CcSEcCtD
Pentoxifylline—Epistaxis—Doxorubicin—bone cancer	0.00113	0.00316	CcSEcCtD
Pentoxifylline—Immune system disorder—Methotrexate—bone cancer	0.00112	0.00314	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—CDK4—bone cancer	0.00111	0.00211	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Cisplatin—bone cancer	0.0011	0.00308	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR downstream signaling—GRM1—bone cancer	0.00109	0.00207	CbGpPWpGaD
Pentoxifylline—Erythema—Methotrexate—bone cancer	0.00108	0.00302	CcSEcCtD
Pentoxifylline—Haemoglobin—Doxorubicin—bone cancer	0.00108	0.00302	CcSEcCtD
Pentoxifylline—Flushing—Epirubicin—bone cancer	0.00108	0.00302	CcSEcCtD
Pentoxifylline—Haemorrhage—Doxorubicin—bone cancer	0.00107	0.00301	CcSEcCtD
Pentoxifylline—Hepatitis—Doxorubicin—bone cancer	0.00107	0.00301	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by NGF—ATF1—bone cancer	0.00107	0.00203	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—RGS1—bone cancer	0.00107	0.00203	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—GRM4—bone cancer	0.00107	0.00203	CbGpPWpGaD
Pentoxifylline—Dysgeusia—Methotrexate—bone cancer	0.00106	0.00296	CcSEcCtD
Pentoxifylline—PDE4B—GPCR downstream signaling—GRM4—bone cancer	0.00105	0.002	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—RGS1—bone cancer	0.00105	0.002	CbGpPWpGaD
Pentoxifylline—Immune system disorder—Epirubicin—bone cancer	0.00105	0.00294	CcSEcCtD
Pentoxifylline—Back pain—Methotrexate—bone cancer	0.00104	0.00292	CcSEcCtD
Pentoxifylline—Arrhythmia—Epirubicin—bone cancer	0.00104	0.0029	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—GRM4—bone cancer	0.00103	0.00197	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—RGS1—bone cancer	0.00103	0.00197	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—ENO2—bone cancer	0.00102	0.00195	CbGpPWpGaD
Pentoxifylline—Vomiting—Cisplatin—bone cancer	0.00102	0.00286	CcSEcCtD
Pentoxifylline—Vision blurred—Methotrexate—bone cancer	0.00102	0.00285	CcSEcCtD
Pentoxifylline—Rash—Cisplatin—bone cancer	0.00101	0.00284	CcSEcCtD
Pentoxifylline—Dermatitis—Cisplatin—bone cancer	0.00101	0.00283	CcSEcCtD
Pentoxifylline—Erythema—Epirubicin—bone cancer	0.00101	0.00283	CcSEcCtD
Pentoxifylline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00101	0.00192	CbGpPWpGaD
Pentoxifylline—Ill-defined disorder—Methotrexate—bone cancer	0.001	0.00281	CcSEcCtD
Pentoxifylline—Anaemia—Methotrexate—bone cancer	0.000997	0.00279	CcSEcCtD
Pentoxifylline—Flushing—Doxorubicin—bone cancer	0.000995	0.00279	CcSEcCtD
Pentoxifylline—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000994	0.00189	CbGpPWpGaD
Pentoxifylline—Flatulence—Epirubicin—bone cancer	0.000994	0.00279	CcSEcCtD
Pentoxifylline—Tension—Epirubicin—bone cancer	0.00099	0.00278	CcSEcCtD
Pentoxifylline—Dysgeusia—Epirubicin—bone cancer	0.000988	0.00277	CcSEcCtD
Pentoxifylline—PDE5A—Hemostasis—PLAU—bone cancer	0.000988	0.00188	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—GRM1—bone cancer	0.000987	0.00188	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—GRM1—bone cancer	0.000987	0.00188	CbGpPWpGaD
Pentoxifylline—Nervousness—Epirubicin—bone cancer	0.00098	0.00275	CcSEcCtD
Pentoxifylline—Back pain—Epirubicin—bone cancer	0.000976	0.00274	CcSEcCtD
Pentoxifylline—Malaise—Methotrexate—bone cancer	0.000972	0.00273	CcSEcCtD
Pentoxifylline—Muscle spasms—Epirubicin—bone cancer	0.00097	0.00272	CcSEcCtD
Pentoxifylline—Immune system disorder—Doxorubicin—bone cancer	0.000969	0.00272	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—RGS1—bone cancer	0.000968	0.00184	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—GRM4—bone cancer	0.000968	0.00184	CbGpPWpGaD
Pentoxifylline—Leukopenia—Methotrexate—bone cancer	0.000965	0.00271	CcSEcCtD
Pentoxifylline—Arrhythmia—Doxorubicin—bone cancer	0.000958	0.00269	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—RGS1—bone cancer	0.000956	0.00182	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—GRM4—bone cancer	0.000956	0.00182	CbGpPWpGaD
Pentoxifylline—Nausea—Cisplatin—bone cancer	0.000953	0.00267	CcSEcCtD
Pentoxifylline—Vision blurred—Epirubicin—bone cancer	0.000951	0.00267	CcSEcCtD
Pentoxifylline—NT5E—Metabolism—DHFR—bone cancer	0.000951	0.00181	CbGpPWpGaD
Pentoxifylline—Ill-defined disorder—Epirubicin—bone cancer	0.000936	0.00263	CcSEcCtD
Pentoxifylline—Convulsion—Methotrexate—bone cancer	0.000934	0.00262	CcSEcCtD
Pentoxifylline—Erythema—Doxorubicin—bone cancer	0.000934	0.00262	CcSEcCtD
Pentoxifylline—Anaemia—Epirubicin—bone cancer	0.000933	0.00262	CcSEcCtD
Pentoxifylline—Agitation—Epirubicin—bone cancer	0.000927	0.0026	CcSEcCtD
Pentoxifylline—ADORA1—GPCR downstream signaling—GRM1—bone cancer	0.000924	0.00176	CbGpPWpGaD
Pentoxifylline—Flatulence—Doxorubicin—bone cancer	0.00092	0.00258	CcSEcCtD
Pentoxifylline—Chest pain—Methotrexate—bone cancer	0.000918	0.00257	CcSEcCtD
Pentoxifylline—Myalgia—Methotrexate—bone cancer	0.000918	0.00257	CcSEcCtD
Pentoxifylline—Tension—Doxorubicin—bone cancer	0.000916	0.00257	CcSEcCtD
Pentoxifylline—Dysgeusia—Doxorubicin—bone cancer	0.000914	0.00256	CcSEcCtD
Pentoxifylline—PDE4B—GPCR downstream signaling—GRM1—bone cancer	0.000913	0.00174	CbGpPWpGaD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000912	0.00256	CcSEcCtD
Pentoxifylline—Malaise—Epirubicin—bone cancer	0.00091	0.00255	CcSEcCtD
Pentoxifylline—Discomfort—Methotrexate—bone cancer	0.000907	0.00254	CcSEcCtD
Pentoxifylline—Nervousness—Doxorubicin—bone cancer	0.000907	0.00254	CcSEcCtD
Pentoxifylline—Leukopenia—Epirubicin—bone cancer	0.000903	0.00253	CcSEcCtD
Pentoxifylline—Back pain—Doxorubicin—bone cancer	0.000903	0.00253	CcSEcCtD
Pentoxifylline—Muscle spasms—Doxorubicin—bone cancer	0.000898	0.00252	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—GRM1—bone cancer	0.000896	0.0017	CbGpPWpGaD
Pentoxifylline—Palpitations—Epirubicin—bone cancer	0.000892	0.0025	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR ligand binding—SMO—bone cancer	0.000889	0.00169	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—GNA11—bone cancer	0.000888	0.00169	CbGpPWpGaD
Pentoxifylline—Confusional state—Methotrexate—bone cancer	0.000887	0.00249	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Methotrexate—bone cancer	0.00088	0.00247	CcSEcCtD
Pentoxifylline—Vision blurred—Doxorubicin—bone cancer	0.00088	0.00247	CcSEcCtD
Pentoxifylline—Convulsion—Epirubicin—bone cancer	0.000874	0.00245	CcSEcCtD
Pentoxifylline—Infection—Methotrexate—bone cancer	0.000874	0.00245	CcSEcCtD
Pentoxifylline—Hypertension—Epirubicin—bone cancer	0.000871	0.00244	CcSEcCtD
Pentoxifylline—PDE4B—Myometrial Relaxation and Contraction Pathways—JUN—bone cancer	0.000869	0.00165	CbGpPWpGaD
Pentoxifylline—Ill-defined disorder—Doxorubicin—bone cancer	0.000866	0.00243	CcSEcCtD
Pentoxifylline—Anaemia—Doxorubicin—bone cancer	0.000863	0.00242	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Methotrexate—bone cancer	0.000862	0.00242	CcSEcCtD
Pentoxifylline—Chest pain—Epirubicin—bone cancer	0.000859	0.00241	CcSEcCtD
Pentoxifylline—Myalgia—Epirubicin—bone cancer	0.000859	0.00241	CcSEcCtD
Pentoxifylline—Agitation—Doxorubicin—bone cancer	0.000858	0.00241	CcSEcCtD
Pentoxifylline—Anxiety—Epirubicin—bone cancer	0.000856	0.0024	CcSEcCtD
Pentoxifylline—ADORA2A—Circadian rythm related genes—CDK4—bone cancer	0.000856	0.00163	CbGpPWpGaD
Pentoxifylline—Skin disorder—Methotrexate—bone cancer	0.000855	0.0024	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000853	0.00239	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Methotrexate—bone cancer	0.000851	0.00239	CcSEcCtD
Pentoxifylline—Discomfort—Epirubicin—bone cancer	0.000849	0.00238	CcSEcCtD
Pentoxifylline—Malaise—Doxorubicin—bone cancer	0.000842	0.00236	CcSEcCtD
Pentoxifylline—Dry mouth—Epirubicin—bone cancer	0.00084	0.00236	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—GRM1—bone cancer	0.000839	0.0016	CbGpPWpGaD
Pentoxifylline—Anorexia—Methotrexate—bone cancer	0.000839	0.00235	CcSEcCtD
Pentoxifylline—Leukopenia—Doxorubicin—bone cancer	0.000836	0.00234	CcSEcCtD
Pentoxifylline—Confusional state—Epirubicin—bone cancer	0.00083	0.00233	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—GRM1—bone cancer	0.000829	0.00158	CbGpPWpGaD
Pentoxifylline—Palpitations—Doxorubicin—bone cancer	0.000825	0.00231	CcSEcCtD
Pentoxifylline—Oedema—Epirubicin—bone cancer	0.000824	0.00231	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Epirubicin—bone cancer	0.000824	0.00231	CcSEcCtD
Pentoxifylline—ADORA2A—GPCR downstream signaling—GRM4—bone cancer	0.000823	0.00156	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—RGS1—bone cancer	0.000823	0.00156	CbGpPWpGaD
Pentoxifylline—Hypotension—Methotrexate—bone cancer	0.000822	0.00231	CcSEcCtD
Pentoxifylline—Infection—Epirubicin—bone cancer	0.000818	0.00229	CcSEcCtD
Pentoxifylline—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000817	0.00155	CbGpPWpGaD
Pentoxifylline—Shock—Epirubicin—bone cancer	0.00081	0.00227	CcSEcCtD
Pentoxifylline—Convulsion—Doxorubicin—bone cancer	0.000809	0.00227	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Epirubicin—bone cancer	0.000806	0.00226	CcSEcCtD
Pentoxifylline—Hypertension—Doxorubicin—bone cancer	0.000806	0.00226	CcSEcCtD
Pentoxifylline—NT5E—Metabolism—CYP3A4—bone cancer	0.000805	0.00153	CbGpPWpGaD
Pentoxifylline—Tachycardia—Epirubicin—bone cancer	0.000804	0.00225	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000802	0.00225	CcSEcCtD
Pentoxifylline—Skin disorder—Epirubicin—bone cancer	0.0008	0.00224	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Epirubicin—bone cancer	0.000796	0.00223	CcSEcCtD
Pentoxifylline—Insomnia—Methotrexate—bone cancer	0.000796	0.00223	CcSEcCtD
Pentoxifylline—Chest pain—Doxorubicin—bone cancer	0.000795	0.00223	CcSEcCtD
Pentoxifylline—Myalgia—Doxorubicin—bone cancer	0.000795	0.00223	CcSEcCtD
Pentoxifylline—Anxiety—Doxorubicin—bone cancer	0.000792	0.00222	CcSEcCtD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.00079	0.0015	CbGpPWpGaD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000789	0.00221	CcSEcCtD
Pentoxifylline—Discomfort—Doxorubicin—bone cancer	0.000785	0.0022	CcSEcCtD
Pentoxifylline—Anorexia—Epirubicin—bone cancer	0.000785	0.0022	CcSEcCtD
Pentoxifylline—Dyspnoea—Methotrexate—bone cancer	0.000785	0.0022	CcSEcCtD
Pentoxifylline—Somnolence—Methotrexate—bone cancer	0.000782	0.00219	CcSEcCtD
Pentoxifylline—Dry mouth—Doxorubicin—bone cancer	0.000777	0.00218	CcSEcCtD
Pentoxifylline—Dyspepsia—Methotrexate—bone cancer	0.000775	0.00217	CcSEcCtD
Pentoxifylline—Hypotension—Epirubicin—bone cancer	0.00077	0.00216	CcSEcCtD
Pentoxifylline—Confusional state—Doxorubicin—bone cancer	0.000768	0.00215	CcSEcCtD
Pentoxifylline—Decreased appetite—Methotrexate—bone cancer	0.000765	0.00215	CcSEcCtD
Pentoxifylline—Oedema—Doxorubicin—bone cancer	0.000762	0.00214	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Doxorubicin—bone cancer	0.000762	0.00214	CcSEcCtD
Pentoxifylline—Infection—Doxorubicin—bone cancer	0.000757	0.00212	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00075	0.0021	CcSEcCtD
Pentoxifylline—Shock—Doxorubicin—bone cancer	0.00075	0.0021	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by GPCR—GRM4—bone cancer	0.000747	0.00142	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—RGS1—bone cancer	0.000747	0.00142	CbGpPWpGaD
Pentoxifylline—Thrombocytopenia—Doxorubicin—bone cancer	0.000746	0.00209	CcSEcCtD
Pentoxifylline—Insomnia—Epirubicin—bone cancer	0.000745	0.00209	CcSEcCtD
Pentoxifylline—Tachycardia—Doxorubicin—bone cancer	0.000744	0.00209	CcSEcCtD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000742	0.00141	CbGpPWpGaD
Pentoxifylline—Skin disorder—Doxorubicin—bone cancer	0.00074	0.00208	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Doxorubicin—bone cancer	0.000737	0.00207	CcSEcCtD
Pentoxifylline—Dyspnoea—Epirubicin—bone cancer	0.000734	0.00206	CcSEcCtD
Pentoxifylline—Somnolence—Epirubicin—bone cancer	0.000732	0.00205	CcSEcCtD
Pentoxifylline—Anorexia—Doxorubicin—bone cancer	0.000726	0.00204	CcSEcCtD
Pentoxifylline—Feeling abnormal—Methotrexate—bone cancer	0.000725	0.00203	CcSEcCtD
Pentoxifylline—Dyspepsia—Epirubicin—bone cancer	0.000725	0.00203	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Methotrexate—bone cancer	0.00072	0.00202	CcSEcCtD
Pentoxifylline—Decreased appetite—Epirubicin—bone cancer	0.000716	0.00201	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—JUN—bone cancer	0.000714	0.00136	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—GRM1—bone cancer	0.000713	0.00136	CbGpPWpGaD
Pentoxifylline—Hypotension—Doxorubicin—bone cancer	0.000712	0.002	CcSEcCtD
Pentoxifylline—Constipation—Epirubicin—bone cancer	0.000704	0.00197	CcSEcCtD
Pentoxifylline—ADORA2B—GPCR downstream signaling—GNA11—bone cancer	0.0007	0.00133	CbGpPWpGaD
Pentoxifylline—Urticaria—Methotrexate—bone cancer	0.000699	0.00196	CcSEcCtD
Pentoxifylline—Body temperature increased—Methotrexate—bone cancer	0.000696	0.00195	CcSEcCtD
Pentoxifylline—Abdominal pain—Methotrexate—bone cancer	0.000696	0.00195	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling by GPCR—SMO—bone cancer	0.000695	0.00132	CbGpPWpGaD
Pentoxifylline—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000694	0.00195	CcSEcCtD
Pentoxifylline—Insomnia—Doxorubicin—bone cancer	0.000689	0.00193	CcSEcCtD
Pentoxifylline—NT5E—Metabolism—GSTP1—bone cancer	0.000689	0.00131	CbGpPWpGaD
Pentoxifylline—Dyspnoea—Doxorubicin—bone cancer	0.000679	0.00191	CcSEcCtD
Pentoxifylline—Feeling abnormal—Epirubicin—bone cancer	0.000679	0.0019	CcSEcCtD
Pentoxifylline—Somnolence—Doxorubicin—bone cancer	0.000677	0.0019	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Epirubicin—bone cancer	0.000673	0.00189	CcSEcCtD
Pentoxifylline—ADORA2B—Signaling Pathways—GRM4—bone cancer	0.000672	0.00128	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—RGS1—bone cancer	0.000672	0.00128	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000672	0.00128	CbGpPWpGaD
Pentoxifylline—Dyspepsia—Doxorubicin—bone cancer	0.000671	0.00188	CcSEcCtD
Pentoxifylline—Decreased appetite—Doxorubicin—bone cancer	0.000662	0.00186	CcSEcCtD
Pentoxifylline—Urticaria—Epirubicin—bone cancer	0.000654	0.00183	CcSEcCtD
Pentoxifylline—Constipation—Doxorubicin—bone cancer	0.000652	0.00183	CcSEcCtD
Pentoxifylline—Abdominal pain—Epirubicin—bone cancer	0.000651	0.00183	CcSEcCtD
Pentoxifylline—Body temperature increased—Epirubicin—bone cancer	0.000651	0.00183	CcSEcCtD
Pentoxifylline—Hypersensitivity—Methotrexate—bone cancer	0.000648	0.00182	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by GPCR—GRM1—bone cancer	0.000648	0.00123	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—GNA11—bone cancer	0.000636	0.00121	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—GNA11—bone cancer	0.000636	0.00121	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—IL3—bone cancer	0.000635	0.00121	CbGpPWpGaD
Pentoxifylline—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000634	0.00121	CbGpPWpGaD
Pentoxifylline—Asthenia—Methotrexate—bone cancer	0.000631	0.00177	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—SMO—bone cancer	0.000631	0.0012	CbGpPWpGaD
Pentoxifylline—Feeling abnormal—Doxorubicin—bone cancer	0.000628	0.00176	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Doxorubicin—bone cancer	0.000623	0.00175	CcSEcCtD
Pentoxifylline—Pruritus—Methotrexate—bone cancer	0.000623	0.00175	CcSEcCtD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000622	0.00118	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—GRM4—bone cancer	0.00061	0.00116	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—RGS1—bone cancer	0.00061	0.00116	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—KIT—bone cancer	0.000607	0.00116	CbGpPWpGaD
Pentoxifylline—Hypersensitivity—Epirubicin—bone cancer	0.000607	0.0017	CcSEcCtD
Pentoxifylline—Urticaria—Doxorubicin—bone cancer	0.000605	0.0017	CcSEcCtD
Pentoxifylline—Body temperature increased—Doxorubicin—bone cancer	0.000602	0.00169	CcSEcCtD
Pentoxifylline—Abdominal pain—Doxorubicin—bone cancer	0.000602	0.00169	CcSEcCtD
Pentoxifylline—Diarrhoea—Methotrexate—bone cancer	0.000602	0.00169	CcSEcCtD
Pentoxifylline—ADORA1—GPCR downstream signaling—GNA11—bone cancer	0.000595	0.00113	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—SMO—bone cancer	0.000591	0.00112	CbGpPWpGaD
Pentoxifylline—Asthenia—Epirubicin—bone cancer	0.000591	0.00166	CcSEcCtD
Pentoxifylline—PDE4B—GPCR downstream signaling—GNA11—bone cancer	0.000588	0.00112	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—SMO—bone cancer	0.000584	0.00111	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—GRM1—bone cancer	0.000583	0.00111	CbGpPWpGaD
Pentoxifylline—Pruritus—Epirubicin—bone cancer	0.000583	0.00163	CcSEcCtD
Pentoxifylline—Dizziness—Methotrexate—bone cancer	0.000582	0.00163	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—GNA11—bone cancer	0.000577	0.0011	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL3—bone cancer	0.000576	0.0011	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—IL3—bone cancer	0.000576	0.0011	CbGpPWpGaD
Pentoxifylline—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000573	0.00109	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RGS1—bone cancer	0.000572	0.00109	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—GRM4—bone cancer	0.000572	0.00109	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—BRAF—bone cancer	0.000571	0.00109	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RGS1—bone cancer	0.000565	0.00107	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—GRM4—bone cancer	0.000565	0.00107	CbGpPWpGaD
Pentoxifylline—Diarrhoea—Epirubicin—bone cancer	0.000563	0.00158	CcSEcCtD
Pentoxifylline—Hypersensitivity—Doxorubicin—bone cancer	0.000561	0.00157	CcSEcCtD
Pentoxifylline—Vomiting—Methotrexate—bone cancer	0.00056	0.00157	CcSEcCtD
Pentoxifylline—Rash—Methotrexate—bone cancer	0.000555	0.00156	CcSEcCtD
Pentoxifylline—Dermatitis—Methotrexate—bone cancer	0.000554	0.00155	CcSEcCtD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000552	0.00105	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—JUN—bone cancer	0.000551	0.00105	CbGpPWpGaD
Pentoxifylline—Headache—Methotrexate—bone cancer	0.000551	0.00155	CcSEcCtD
Pentoxifylline—Asthenia—Doxorubicin—bone cancer	0.000547	0.00153	CcSEcCtD
Pentoxifylline—Dizziness—Epirubicin—bone cancer	0.000545	0.00153	CcSEcCtD
Pentoxifylline—ADORA1—Signaling by GPCR—GNA11—bone cancer	0.000541	0.00103	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—IL3—bone cancer	0.00054	0.00103	CbGpPWpGaD
Pentoxifylline—Pruritus—Doxorubicin—bone cancer	0.000539	0.00151	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—GNA11—bone cancer	0.000534	0.00102	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—IL3—bone cancer	0.000533	0.00101	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—GRM1—bone cancer	0.000529	0.00101	CbGpPWpGaD
Pentoxifylline—Vomiting—Epirubicin—bone cancer	0.000524	0.00147	CcSEcCtD
Pentoxifylline—PDE4A—Signaling by GPCR—IL3—bone cancer	0.000523	0.000996	CbGpPWpGaD
Pentoxifylline—Nausea—Methotrexate—bone cancer	0.000523	0.00147	CcSEcCtD
Pentoxifylline—Diarrhoea—Doxorubicin—bone cancer	0.000521	0.00146	CcSEcCtD
Pentoxifylline—Rash—Epirubicin—bone cancer	0.000519	0.00146	CcSEcCtD
Pentoxifylline—Dermatitis—Epirubicin—bone cancer	0.000519	0.00145	CcSEcCtD
Pentoxifylline—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000517	0.000982	CbGpPWpGaD
Pentoxifylline—Headache—Epirubicin—bone cancer	0.000516	0.00145	CcSEcCtD
Pentoxifylline—Dizziness—Doxorubicin—bone cancer	0.000504	0.00141	CcSEcCtD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000498	0.000947	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—GRM1—bone cancer	0.000496	0.000943	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL3—bone cancer	0.00049	0.000932	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—GRM1—bone cancer	0.00049	0.000931	CbGpPWpGaD
Pentoxifylline—Nausea—Epirubicin—bone cancer	0.000489	0.00137	CcSEcCtD
Pentoxifylline—Vomiting—Doxorubicin—bone cancer	0.000484	0.00136	CcSEcCtD
Pentoxifylline—PDE4B—Signaling by GPCR—IL3—bone cancer	0.000484	0.000921	CbGpPWpGaD
Pentoxifylline—Rash—Doxorubicin—bone cancer	0.00048	0.00135	CcSEcCtD
Pentoxifylline—Dermatitis—Doxorubicin—bone cancer	0.00048	0.00135	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by NGF—MDM2—bone cancer	0.000478	0.00091	CbGpPWpGaD
Pentoxifylline—Headache—Doxorubicin—bone cancer	0.000477	0.00134	CcSEcCtD
Pentoxifylline—ADORA1—Circadian rythm related genes—TP53—bone cancer	0.000471	0.000897	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—GNA11—bone cancer	0.00046	0.000874	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—SMO—bone cancer	0.000456	0.000868	CbGpPWpGaD
Pentoxifylline—Nausea—Doxorubicin—bone cancer	0.000453	0.00127	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling Pathways—RGS1—bone cancer	0.000441	0.000839	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GRM4—bone cancer	0.000441	0.000839	CbGpPWpGaD
Pentoxifylline—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000434	0.000825	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000428	0.000814	CbGpPWpGaD
Pentoxifylline—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	0.000425	0.000808	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—GNA11—bone cancer	0.000417	0.000794	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—IL3—bone cancer	0.000417	0.000793	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SMO—bone cancer	0.000411	0.000781	CbGpPWpGaD
Pentoxifylline—PDE5A—Hemostasis—TP53—bone cancer	0.000397	0.000755	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000391	0.000744	CbGpPWpGaD
Pentoxifylline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000391	0.000744	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GRM1—bone cancer	0.000383	0.000728	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL3—bone cancer	0.000378	0.00072	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—GNA11—bone cancer	0.000376	0.000714	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SMO—bone cancer	0.000373	0.000709	CbGpPWpGaD
Pentoxifylline—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000371	0.000706	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000366	0.000696	CbGpPWpGaD
Pentoxifylline—ADORA2A—Circadian rythm related genes—TP53—bone cancer	0.000364	0.000692	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—PTGS2—bone cancer	0.000357	0.000679	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—ATF1—bone cancer	0.000349	0.000664	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SMO—bone cancer	0.000349	0.000664	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SMO—bone cancer	0.000345	0.000656	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—GNA11—bone cancer	0.000341	0.000649	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL3—bone cancer	0.000341	0.000648	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by NGF—EGFR—bone cancer	0.000327	0.000622	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—GNA11—bone cancer	0.000319	0.000607	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—ATF1—bone cancer	0.000317	0.000603	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—GNA11—bone cancer	0.000316	0.0006	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL3—bone cancer	0.000309	0.000588	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ATF1—bone cancer	0.000297	0.000565	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ATF1—bone cancer	0.000293	0.000558	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TGFBR2—bone cancer	0.000291	0.000554	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL3—bone cancer	0.00029	0.000551	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL3—bone cancer	0.000286	0.000544	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IGF1R—bone cancer	0.000274	0.000521	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SMO—bone cancer	0.00027	0.000513	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TGFBR2—bone cancer	0.000264	0.000503	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NDUFA12—bone cancer	0.00026	0.000495	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IGF1R—bone cancer	0.000249	0.000473	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TGFBR2—bone cancer	0.000248	0.000471	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GNA11—bone cancer	0.000247	0.000469	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TGFBR2—bone cancer	0.000245	0.000465	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IGF1R—bone cancer	0.000233	0.000443	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IGF1R—bone cancer	0.00023	0.000438	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ATF1—bone cancer	0.000229	0.000436	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL3—bone cancer	0.000224	0.000425	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NT5C3A—bone cancer	0.000216	0.00041	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KIT—bone cancer	0.000199	0.000378	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TGFBR2—bone cancer	0.000191	0.000364	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—BRAF—bone cancer	0.000187	0.000355	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—EGFR—bone cancer	0.000181	0.000344	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KIT—bone cancer	0.00018	0.000343	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1R—bone cancer	0.00018	0.000342	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—BRAF—bone cancer	0.00017	0.000323	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KIT—bone cancer	0.000169	0.000321	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KIT—bone cancer	0.000167	0.000318	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—EGFR—bone cancer	0.000164	0.000313	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—BRAF—bone cancer	0.000159	0.000302	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—BRAF—bone cancer	0.000157	0.000299	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MDM2—bone cancer	0.000157	0.000298	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—EGFR—bone cancer	0.000154	0.000293	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—EGFR—bone cancer	0.000152	0.000289	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MDM2—bone cancer	0.000142	0.00027	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—JUN—bone cancer	0.000136	0.000259	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MDM2—bone cancer	0.000133	0.000253	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—bone cancer	0.000132	0.000252	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MDM2—bone cancer	0.000132	0.00025	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KIT—bone cancer	0.00013	0.000248	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—JUN—bone cancer	0.000124	0.000235	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—BRAF—bone cancer	0.000123	0.000233	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—bone cancer	0.00012	0.000229	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—EGFR—bone cancer	0.000119	0.000226	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—JUN—bone cancer	0.000116	0.00022	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—JUN—bone cancer	0.000114	0.000217	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—bone cancer	0.000113	0.000214	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—bone cancer	0.000111	0.000212	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EGFR—bone cancer	0.000107	0.000203	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MDM2—bone cancer	0.000103	0.000195	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EGFR—bone cancer	9.71e-05	0.000185	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ENO2—bone cancer	9.44e-05	0.00018	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EGFR—bone cancer	9.09e-05	0.000173	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EGFR—bone cancer	8.99e-05	0.000171	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TP53—bone cancer	8.98e-05	0.000171	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—JUN—bone cancer	8.93e-05	0.00017	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—DHFR—bone cancer	8.76e-05	0.000167	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—bone cancer	8.69e-05	0.000165	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GNA11—bone cancer	8.19e-05	0.000156	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TP53—bone cancer	8.15e-05	0.000155	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TP53—bone cancer	7.64e-05	0.000145	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TP53—bone cancer	7.55e-05	0.000144	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP3A4—bone cancer	7.42e-05	0.000141	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.38e-05	0.00014	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGFR—bone cancer	7.02e-05	0.000134	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTP1—bone cancer	6.35e-05	0.000121	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TP53—bone cancer	5.9e-05	0.000112	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—bone cancer	3.29e-05	6.25e-05	CbGpPWpGaD
